MECHANISTIC DRUG SAFETY INTELLIGENCE PLATFORM 

Cytocast is a TechBio company developing the CYTOCAST DIGITAL TWIN Platform™ for mechanistic drug safety prediction. 

We help pharmaceutical teams identify and understand side-effect risks early—before costly late-stage failure—by modeling how compounds perturb targets, pathways, and human tissues. 

INDUSTRY CONTEXT 

The pharmaceutical industry is transitioning from empirical safety assessment toward mechanistic, model-based approaches. Cytocast is part of this shift—enabling earlier, more predictive safety evaluation aligned with emerging new directions.

SCIENCE

The CYTOCAST DIGITAL TWIN Platform™ integrates systems biology, artificial intelligence, and molecular simulation to model how drugs perturb biological systems and lead to clinical side effects. 

Our platform connects: 
compound → targets & off-targets → perturbed pathways → clinical side effects, 
enabling earlier, more informed decisions in drug discovery. 

WHAT MAKES CYTOCAST DIFFERENT 

• Mechanistic, not black-box predictions 
• System-level modeling
• Human-relevant safety insight beyond toxicity proxies 
• Clinically interpretable outputs for decision-making 
• Safety-first approach, complementing efficacy-driven discovery 

USE CASES 

• Early safety risk screening in drug discovery 
• Lead vs backup compound selection 
• Mechanistic investigation of adverse effects 
• Portfolio-level safety comparison and prioritization 

VISION 

We believe drug safety should be predictable, not reactive. 
Our vision is to make mechanistic, human-relevant safety model

TEAM 

Our team combines expertise in systems biology, computational biology, high-performance computing, and drug discovery—bridging scientific rigor with scalable technology. 

GET IN TOUCH 

📬 Contact us if you: 
• want to evaluate early safety risk in your pipeline 
• are exploring model-informed drug development approaches 
• are interested in collaboration or partnership

Cytocast

Org chart

Teams

Offices